摘要:
The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要:
An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.
摘要:
The present invention relates to methods, apparatus and computer program products for selecting siRNAs, antisense polynucleotides, and other hybridizing polynucleotides. In particular, the invention relates to methods for selecting siRNAs, antisense polynucleotides, and other hybridizing polynucleotides that have moderate or low off-target activity.
摘要:
An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.
摘要:
Method and Apparatus for using successively joined carbon electrodes (that are not coated with a metal) shaped with a projection at one end and a socket at the other end. In order for the user to know the existing length of the electrode performing the gouging this electrode is marked with a notch, ink or material which changes its color at elevated temperatures at 80 mm, 60 mm, and 40 mm.
摘要:
A carbon rod assembly is disclosed which includes a first carbon rod piece having a projection at one end thereof and a second carbon rod piece having a socket hole at one end thereof. External and internal screw threads of 1/2 to 3 turns are formed on the projection and socket hole respectively, so that the first and second carbon rod pieces are firmly connected by inserting the projection into the socket hole and thereafter rotating the carbon rod pieces relative to each other.
摘要:
A carbon rod assembly is disclosed which includes a first carbon rod piece having a projection at one end thereof and a second carbon rod piece having a socket hole at one end thereof. External and internal screw threads of 1/2 to 3 turns are formed on the projection and socket hole respectively, so that the first and second carbon rod pieces are firmly connected by inserting the projection into the socket hole and thereafter rotating the carbon rod pieces relative to each other.
摘要:
The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要:
The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要:
An automatic analyzer capable of avoiding carry-over between samples, and a sample dispensing method, are provided. To that end, an automatic analyzer (1) for performing analysis of both assay menu with a high carry-over avoiding level and assay menu with a low carry-over avoiding level, includes: a first sample dispensing apparatus (6) loaded with a disposable tip (60a) for sample dispensing for assay menu with a high carry-over avoiding level, and for subdividing and dispensing a sample for assay menu with a low carry-over avoiding level; an aliquot container (9) for subdividing and containing a sample for assay menu with a low carry-over avoiding level, subdivided and dispensed by the first sample dispensing apparatus (6); and a second sample dispensing apparatus (5) loaded with a reusable probe (50), for sample dispensing for assay menu with a low carry-over avoiding level.